Skip to content

Atorvastatin effect on COVID-19

Atorvastatin effect in Clinical and Laboratory findings of patiens with COVID-19 admitted RAZI referral hospital in Mazandaran State: A Randomized Clinical Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190727044343N2
Enrollment
100
Registered
2020-04-19
Start date
2020-04-05
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Disease 2019 (COVID-19). COVID-19

Interventions

Intervention 1: Intervention group: Oral Atorvastatin 40 mg for 5 days. Intervention 2: Control group: Routine Care.

Sponsors

Mazandaran University of Medical Sceinces
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Confirmed COVID-19 Diagnosis No prior Cardiovascular Disease No history of Statins use Chloroquine use No prior Kaletra usage No prior liver damage No prior myositis

Exclusion criteria

Exclusion criteria: Prior Kaletra Use Cardiovascular Disease Prior myositis Prior Liver damage

Design outcomes

Primary

MeasureTime frame
CRP level in Blood. Timepoint: At the beginning of the study at after 5 consecutive days. Method of measurement: Blood sampling and CRP measuring.

Secondary

MeasureTime frame
Mortality during the study. Timepoint: from the beginning of the study until discharge. Method of measurement: Observing.;Duration of recovery. Timepoint: From the beginning of the study until discharge. Method of measurement: Observing and case file review.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLotfollah Davoodi

Mazandaran University of Medical Sciences

Lotfdavoodi@yahoo.com+98 11 4221 8231

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026